Since its creation in 1981, Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics.

Over the years, we have not wavered in our commitment to advance our products and technologies. Thanks to the hard work and dedication of our passionate team, we are now a leading contract manufacturing organization (CMO) for small molecule APIs.

We can support your products at every stage of the lifecycle, from early phase development to large scale manufacturing. Our diverse small molecule portfolio continues to help us to expand into new and growing markets.

You can read about our history below.

Cambrex significantly expands its cGMP API manufacturing and storage capabilities in Charles City, Iowa. The company also increases its large scale manufacturing capability in Karlskoga, Sweden, with the installation of new multi-purpose reactors and control room upgrades. Cambrex opens a new pilot plant at its site in Paullo (Milan) Italy, allowing greater speed and flexibility for small scale API production.

Cambrex expands its clinical stage API capabilities with the acquisition of PharmaCore, Inc. in High Point, North Carolina, a leading early phase chemistry specialist with expertise in developing, scaling up and manufacturing small molecule APIs for clinical phase projects.

Completion of 45,000 sq. ft. temperature and humidity controlled cGMP warehouse space at Cambrex Charles City.

Cambrex Charles City completes a major 7,000 sq. ft. facility expansion to increase API manufacturing capabilities for both existing products and a new product.

To broaden its biocatalysis offering, Cambrex acquires IEP GmbH in Wiesbaden, Germany.

Cambrex Paullo, (Milan), Italy completes the addition of a new cGMP API production facility.

Cambrex expands its group of world class R&D chemists by acquiring Prosyntest in Tallinn, Estonia. Steven Klosk is appointed as CEO while remaining President. Cambrex Charles City completes the addition of a high potency development center.

Cambrex obtains DEA licensing for controlled substance API manufacturing.

Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry businesses, Nobel Chemicals AB and Profarmaco S.r.l., located in Karlskoga, Sweden and Paullo, Milan, Italy.

Cambrex enters the life sciences arena with the acquisition of Salsbury Chemicals, a manufacturer of bulk intermediates and APIs, as well as high-level research in nitration chemistry, and Zeeland Chemicals, producer of specialty intermediates and hydrogenation chemistry. The Charles City site is established.

Cambrex is listed on the New York Stock Exchange (NYSE).

The company changes its name to Cambrex Corporation and becomes listed on the NASDAQ.

Originally named CasChem, the company is founded when the castor oil and derivatives product lines are acquired from NL Industries.